
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced preliminary data from the first 10 patients in the safety cohort of ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate …
Read More